Sugi Predict

Sugi Predict / Compounds / SCHEMBL26215427

SCHEMBL26215427

SCHEMBL26215427

CC(C)(C)OC(=O)Nc1c(-c2ccc([N+](=O)[O-])cc2)nsc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 2/20 0.40
▸ BECN1 Q14457 2/20 0.40
▸ MAPT P10636 6/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ RECQL P46063 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ PSMB8 P28062 1/20 0.39
▸ ABCC8 Q09428 1/20 0.37
▸ KCNJ11 Q14654 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ SLC29A1 Q99808 1/20 0.37
▸ MMP1 P03956 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31680217 0.84 FFAR4 (0.42) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL29042310 0.74 ABCC8 (0.42) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL26215431 0.73 ABCC8 (0.44) MAPTSMN1; SMN2MEN1KMT2AABCC8
SCHEMBL29042302 0.73 ABCC8 (0.41) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL14710784 0.72 TSHR (0.44) BCL2BECN1MAPTSMN1; SMN2MEN1
SCHEMBL26215430 0.72 AR (0.54) MAPTSMN1; SMN2L3MBTL1RAB9ANPC1
SCHEMBL26215428 0.71 ABCC8 (0.47) MAPTSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL1532248 0.71 KMT2A (0.59) BCL2BECN1MAPTSMN1; SMN2MEN1
SCHEMBL28708806 0.70 MAPT (0.39) BCL2BECN1MAPTSMN1; SMN2MEN1
SCHEMBL27930246 0.69 XDH (0.45) BCL2BECN1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof BRIDGENE BIOSCIENCES, INC. (US) 2026-03-24 — — US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 — — US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 — — US disclosed
EP-4175658-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF Bridgene Biosciences, Inc. (US) 2023-05-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof YAP1, TEAD1, TEAD2 BCL2 2122/4885BECN1 2389/4885MAPT 371/4885
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF TEAD1, TEAD2, TEAD3 BCL2 2331/4885BECN1 1632/4885MAPT 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.